HCAT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
70.5M
-0.4%
70.8M
-5.3%
74.7M
-2.2%
76.3M
-5.4%
80.7M
Cost of Revenue
35.6M
+0.9%
35.3M
-0.0%
35.3M
-8.3%
38.5M
-9.4%
42.5M
Gross Profit
34.9M
-1.7%
35.5M
-10.0%
39.4M
+4.1%
37.8M
-1.1%
38.2M
Operating Expenses
71.3M
-49.7%
141.9M
+13.1%
125.5M
+126.8%
55.3M
-26.6%
75.3M
R&D
11.0M
+12.8%
9.8M
-1.3%
9.9M
-19.3%
12.3M
-0.9%
12.4M
SG&A
22.3M
-9.2%
24.5M
+15.7%
21.2M
-30.3%
30.4M
+41.6%
21.5M
Operating Income
-36480000
+65.7%
-106477000
-23.7%
-86080000
-391.6%
-17509000
+52.8%
-37094000
EBITDA
1.5M
+35.7%
1.1M
-86.2%
8.3M
+268.7%
-4895000
-212.3%
4.4M
Net Income
-40537000
+63.5%
-111026000
-22.0%
-91025000
-309.5%
-22229000
+45.8%
-40978000
EPS (Basic)
$-0.55
+64.1%
$-1.53
-19.5%
$-1.28
-300.0%
$-0.32
+45.8%
$-0.59
EPS (Diluted)
$-0.55
+64.1%
$-1.53
-19.5%
$-1.28
-300.0%
$-0.32
+45.8%
$-0.59
Shares (Diluted)
74.0M
+1.9%
72.6M
+2.2%
71.0M
+0.9%
70.4M
+1.1%
69.6M
Health Catalyst (HCAT) โ€” Financials